Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30163569 | 1.00 | KCNH2 (0.46) | KCNH2HRH3CYP1A2KDM4ELMNA | |
| SCHEMBL31428611 | 0.74 | HRH3 (0.47) | KCNH2HRH3KDM4ELMNAPOLB | |
| SCHEMBL31682518 | 0.70 | GRIN2B (0.50) | RAB9AOPRK1 | |
| SCHEMBL375294 | 0.69 | KDM1A (0.37) | CYP1A2KDM4EPOLB | |
| SCHEMBL29518266 | 0.69 | CYP1A2 (0.57) | KCNH2HRH3CYP1A2KDM4ELMNA | |
| SCHEMBL1206321 | 0.69 | CYP1A2 (0.57) | KCNH2HRH3CYP1A2KDM4ELMNA | |
| SCHEMBL21618429 | 0.69 | CYP1A2 (0.61) | KCNH2HRH3CYP1A2KDM4ELMNA | |
| SCHEMBL24977046 | 0.67 | KCNH2 (0.36) | KCNH2HRH3KDM4EHCAR2NPC1 | |
| SCHEMBL31429023 | 0.67 | KCNH2 (0.36) | KCNH2HRH3KDM4EHCAR2NPC1 | |
| SCHEMBL31428845 | 0.67 | KCNH2 (0.36) | KCNH2HRH3KDM4EHCAR2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-03-20 | — | — | US | disclosed |
| WO-2023008577-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | 国立大学法人神戸大学 | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | BRAF, RAF1, NRAS | KCNH2 3703/4885HRH3 2324/4885CYP1A2 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.